Neutralizing Antibody Response Assessment for a Phase 2/3 Randomized, Observer-Blind, Placebo-Controlled, Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccin
Administered By
Awarded By
Contributors
- Beerman, Rebecca Program Manager
- Montefiori, David Charles Principal Investigator
- Sarzotti-Kelsoe, Marcella Director
- Shen, Xiaoying Co Investigator
Start/End
- April 2, 2021 - March 31, 2023